Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Schwab, Jan-Alexander; Wolf, Hendrik; Schnitker, J; Wüstenberg, Eike

doi:10.1007/s41030-018-0050-1

Search citation statements

Order By: Relevance

Paper Sections

Select...

Post-marketing Authorization Studies1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The good tolerability was associated with high satisfaction and compliance. [26][27][28] Attempts to improve compliance had been also reported postmarketing. Alesina et al investigated if compliance can be increased by providing the patients an Compliance electronic device (CED) (Memozax; a tablet container with a programmable daily acoustic alarm).…”

Section: Post-marketing Authorization Studiesmentioning

confidence: 99%

GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization

Barber

Rico

Blanco

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Allergen immunotherapy has been used for more than 100 y, but only recently underlying immunological mechanisms have started to be understood. New Allergy vaccines are now considered to be full pharmaceutical products, that should comply with general as well as specific pharmaceutical legal framework. GRAZAX® is the first global allergy vaccine developed in compliance with the new legal environment and is thus a reference for developing new allergy vaccines. Here, we provide a rationale description of GRAZAX®, providing a sequential description of its pharmaceutical and clinical development. With more than 25 clinical trials, involving more than 8000 patients, including as well three 5-y prospective clinical trials, GRAZAX® is a key product to understand the unique position of allergen-specific immunotherapy as a disease-modifying intervention.

show abstract

Section: Post-marketing Authorization Studiesmentioning

confidence: 99%